Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
274 hedge funds and large institutions have $4.55B invested in Intra-Cellular Therapies Inc. in 2023 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 110 increasing their positions, 86 reducing their positions, and 44 closing their positions.
277% more call options, than puts
Call options by funds: $54.4M | Put options by funds: $14.4M
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
28% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 86
4% more capital invested
Capital invested by funds: $4.38B → $4.55B (+$166M)
3% less funds holding
Funds holding: 283 → 274 (-9)
16% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$82.2M |
| 2 |
DM
Deerfield Management
New York
|
+$35.5M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$23.6M |
| 4 |
ClearBridge Investments
New York
|
+$18.9M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$17.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$43.4M |
| 2 |
Holocene Advisors
New York
|
-$29.7M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$26.7M |
| 4 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$21.9M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$20.7M |
ITCI Hedge Fund Activity: Q1 2023 in Review
274 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2023, worth a combined $4.55B — up 3.8% from $4.38B a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of ITCI and 37 opened new positions — a net loss of 7 holders — while 86 trimmed existing stakes and 110 added.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $82.2M. The largest seller was Millennium Management, cutting an estimated $43.4M.
- 274 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2023, down from 283 in Q4 2022.
- Funds reported $4.55B of Intra-Cellular Therapies Inc. stock for Q1 2023, up 3.8% quarter-over-quarter.
- 37 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2023 and 44 closed out, a net change of -7 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q1 2023 was Deep Track Capital, an estimated $82.2M added.
- The largest Intra-Cellular Therapies Inc. seller in Q1 2023 was Millennium Management, an estimated $43.4M sold.
Based on aggregated 13F filings for Q1 2023.